Biosyent Inc. (CVE:RX) price target lowered to C$10.00 by Raymond James

ME Staff
-
0

Analyst Ratings For Biosyent Inc. (CVE:RX)

Today, Raymond James lowered its price target on Biosyent Inc. (CVE:RX) to C$10.00 per share.

There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Biosyent Inc. (CVE:RX) is Buy with a consensus target price of C$10.00 per share, a potential 33.33% upside.

Some recent analyst ratings include

  • 3/22/2018-Biosyent Inc. (CVE:RX) had its Accumulate rating reiterated by Bloom Burton

    Recent Trading Activity for Biosyent Inc. (CVE:RX)
    Shares of Biosyent Inc. closed the previous trading session at 7,50 0,00 0,00 % with shares trading hands.